Business
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Nurix to report additional preclinical data for its targeted BTK degraders NX-2127 and NX-5948 SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Nurix
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"Nurix to report additional preclinical data for its targeted BTK degraders NX-2127 and NX-5948\nSAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that preclinical data from its targeted protein degradation programs, NX-2127 and NX-5948, will be presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting, which is being held from April 14-19, 2023, in Orlando, FL. NX-2127 and NX-5948 are orally available targeted protein degraders of Bruton’s tyrosine kinase (BTK) that are being evaluated in ongoing Phase 1 clinical trials in patients with relapsed or refractory B cell malignancies. Details of the AACR Presentation Abstracts Title: NX-2127: A first-in-class clinical-stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies Session Type: MinisymposiumPresenting Author: Jeffrey Mihalic, Ph.D., Senior Director, Medicinal ChemistrySession Category: ChemistrySession Title: New Targeted Protein Degraders and Novel Design StrategiesSession Date and Time: Monday April 17, 2023, 2:30 PM – 4:30 PM ETPublished Abstract Number: 3423 Title: NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants Session Category: Experimental and Molecular TherapeuticsPresenting Author: Mark Noviski, Ph.D., Senior Scientist, Cell Biology & Project LeadSession Title: Strategies for Reversal of Drug ResistanceSession Date and Time: Monday April 17, 2023, 1:30 PM - 5:00 PM ETLocation: Section 20Poster Board Number: 8Abstract Presentation Number: 2850 All presentations and posters will be available to registered attendees for on-demand viewing on the AACR website on April 14, 2023, beginning at 4:30 PM ET. Upon release at AACR, Nurix’s presentations will also be available on the Posters and Presentations section of the scientific resources page of Nurix’s website. About NX-2127NX-2127 is a novel bifunctional molecule that degrades BTK and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing cli...